Eurofins-Cerep SA
ALECR
Company Profile
Business description
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
Contact
Le bois l Eveque
Celle l Evescault86600
FRAT: +33 549893000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
207
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.40 | 0.70 | -0.01% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,650.66 | 142.85 | 0.58% |
| NASDAQ | 20,650.13 | 472.31 | -2.24% |
| Nikkei 225 | 40,234.63 | 564.97 | -1.38% |
| NZX 50 Index | 12,684.04 | 45.36 | -0.36% |
| S&P 500 | 6,238.01 | 101.38 | -1.60% |
| S&P/ASX 200 | 8,657.40 | 4.60 | -0.05% |
| SSE Composite Index | 3,566.50 | 6.55 | 0.18% |